Coagulation factor VII precursor
Coagulation factor VII precursor Brand names, Coagulation factor VII precursor Analogs
Coagulation factor VII precursor Brand Names Mixture
- No information avaliable
Coagulation factor VII precursor Chemical_Formula
C1972H3076N560O597S28
Coagulation factor VII precursor RX_link
http://www.rxlist.com/cgi/generic3/novoseven.htm
Coagulation factor VII precursor fda sheet
Coagulation factor VII precursor msds (material safety sheet)
Coagulation factor VII precursor Synthesis Reference
No information avaliable
Coagulation factor VII precursor Molecular Weight
45079.1
Coagulation factor VII precursor Melting Point
58 oC (Petersen, L.C. et al., Eur. J. Biochem 261: 124-129 (1999)).
Coagulation factor VII precursor H2O Solubility
No information avaliable
Coagulation factor VII precursor State
Liquid
Coagulation factor VII precursor LogP
-0.311
Coagulation factor VII precursor Dosage Forms
Solution (IV injection); Solution (IV infusion); Tablet; Powder for solution
Coagulation factor VII precursor Indication
For treatment of hemorrhagic complications in hemophilia A and B
Coagulation factor VII precursor Pharmacology
Used in the treatment of bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and, when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.
Coagulation factor VII precursor Absorption
No information avaliable
Coagulation factor VII precursor side effects and Toxicity
No information avaliable
Coagulation factor VII precursor Patient Information
No information avaliable
Coagulation factor VII precursor Organisms Affected
Humans and other mammals
